BioMérieux
| Company type | Société Anonyme |
|---|---|
| Euronext Paris: BIM
CAC Next 20 component | |
| ISIN | FR0013280286 |
| Industry | Biotechnology |
| Founded | 1963 |
| Founder | Dr Alain Mérieux |
| Headquarters | Marcy-l'Étoile, France |
Area served | Worldwide |
Key people | Pierre Boulud (CEO) Alexandre Mérieux (Chairman) Dr Marcel Mérieux Dr Charles Mérieux |
| Products | in vitro diagnostics |
| Revenue | €3.1 billion (2020) |
| 587,000,000 euro (2022) | |
| 452,000,000 euro (2022) | |
Number of employees | 12,800 (2020) |
| Website | www |
bioMérieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, close to Lyon. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.
bioMérieux provides diagnostic solutions (reagents, instruments, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock exchange (BIM – ISIN: FR0013280286).